Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Urogen Pharma (URGN : NSDQ)

• Company Description    UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. Number of Employees: 291

• Price / Volume Information    Yesterday's Closing Price: $28.89 Daily Weekly Monthly 20 Day Moving Average: 920,799 shares Shares Outstanding: 48.72 (millions) Market Capitalization: $1,407.58 (millions) Beta: 1.58 52 Week High: $32.37 52 Week Low: $3.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 18.84% 13.03% 12 Week 36.40% 26.10% Year To Date 23.36% 17.30%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 Alexander Park Drive - Princeton,NJ 08540 USA ph: 646-768-9780 fax: - vincent.perrone@urogen.com http://www.urogen.com

• General Corporate Information    Officers Elizabeth Barrett - Chief Executive Officer and President Arie Belldegrun - Chair Chris Degnan - Chief Financial Officer Cynthia Butitta - Director Leana S. Wen - Director Peer Information Urogen Pharma (CORR.) Urogen Pharma (RSPI) Urogen Pharma (CGXP) Urogen Pharma (BGEN) Urogen Pharma (GTBP) Urogen Pharma (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M96088105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 48.72 Most Recent Split Date: (:1) Beta: 1.58 Market Capitalization: $1,407.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.42 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.98 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 10.02 EPS Growth vs. Year Ago Period: 48.91% vs. Previous Quarter: 12.96% Sales Growth vs. Year Ago Period: 151.60% vs. Previous Quarter: 34.68% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -62.85 12/31/25 - -72.93 09/30/25 - -71.04 Current Ratio 03/31/26 - 4.69 12/31/25 - 4.01 09/30/25 - 3.99 Quick Ratio 03/31/26 - 4.28 12/31/25 - 3.65 09/30/25 - 3.79 Operating Margin 03/31/26 - -94.83 12/31/25 - -139.81 09/30/25 - -170.59 Net Margin 03/31/26 - -94.83 12/31/25 - -139.81 09/30/25 - -170.59 Pre-Tax Margin 03/31/26 - -98.45 12/31/25 - -139.74 09/30/25 - -167.48 Book Value 03/31/26 - -2.55 12/31/25 - -2.25 09/30/25 - -2.49 Inventory Turnover 03/31/26 - 1.08 12/31/25 - 1.26 09/30/25 - 1.44 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©